McKesson at Morgan Stanley conference: outlook rises on oncology push

McKesson raised FY2027 adjusted EPS guidance by $0.40 to $44.20-$45.00, implying 13%-15% reported growth, supported by broad-based performance across its pharmaceutical, oncology and RxTS businesses. Oncology & Multispecialty delivered 33% revenue growth and 41% adjusted operating-profit growth, while North American Pharmaceutical operating income rose 19%; Medsurg remained a weak spot, with operating profit down about 20%. McKesson also agreed to acquire Precision Medicine Group to expand oncology clinical-research capabilities, repurchased $2.5B of its planned $5B buyback in Q1, raised its dividend 15%, and remains on track for a potential Wellverse IPO in H2 2027.

Analysis

MCK’s incremental earnings power is increasingly tied to assets with materially better durability than wholesale distribution: specialty practice services, trial enablement and workflow software monetize patient volume multiple times. The strategic value of Precision Medicine Group is not standalone CRO revenue but the ability to raise community-trial enrollment and enrich Ontada’s real-world dataset; if integrated well, this supports a higher recurring-services mix and a gradual valuation rerating versus distributor peers CAH and ABC/Cencora (COR). Financial accretion remains a management assertion until purchase price, financing and closing conditions are disclosed.

Near-term, the guidance increase and accelerated repurchase execution should support estimates and reduce the effective float, but the magnitude is unlikely to justify chasing a large gap-up given known second-half technology and automation spend. The more consequential 1-3 month catalyst is contract-renewal visibility with CVS: renewal removes an avoidable revenue-concentration discount, while a pricing concession could offset operating leverage despite retained volume. Watch branded-launch/generic-conversion economics, which can create quarterly profit volatility that the current growth narrative may underappreciate.

Over 6-18 months, the Wellverse separation is a quality-of-earnings catalyst only if RemainCo receives a clear multiple premium while the separated entity demonstrates credible margin recovery. Apollo’s minority valuation is a useful reference point, not a public-market clearing price; softer seasonal demand or failed private-label/productivity initiatives could impair IPO readiness. The principal structural downside is Part B/MFN implementation shifting economics away from community oncology, even if policymakers ultimately pursue a rebate-based alternative; regulatory specificity, not management confidence, is the falsification point.

Contrarian view: MCK may be less a defensive distributor and more an underappreciated healthcare-services compounder, but that thesis requires services growth to remain organic after acquisition normalization. A better expression than outright sector beta is MCK versus CAH, where MCK’s oncology, data and trial infrastructure should command superior earnings durability if policy remains benign.

Key Decisions for Investors

• Initiate a 3-6 month long MCK / short CAH pair on equal-dollar exposure after confirmation that MCK holds its post-guidance trading range; target 8-12% relative upside from estimate revisions and mix-driven multiple separation. Exit if MCK reduces full-year operating-income expectations or discloses material CVS economics deterioration.
• Add to MCK on any 5-7% policy- or Medsurg-driven pullback rather than chase immediate strength; base case is mid-teens EPS compounding plus buyback support, with upside contingent on Precision Medicine Group terms. Do not underwrite acquisition synergies until consideration, leverage impact and expected close are disclosed.
• Set an event alert around CVS renewal milestones through June 2027. A renewal without unusual pricing concessions is a de-risking catalyst; evidence of lower distributor economics warrants reducing MCK and reassessing the long/short pair.
• Monitor CMS detail on Part B/MFN pricing and adoption of a rebate-style alternative over the next 6-12 months. Any rule that compresses community-practice drug economics without an offsetting rebate mechanism is a thesis break for MCK’s oncology-services premium.
• Avoid using APO as a direct read-through on MCK’s separation value: Apollo’s minority investment provides optional validation, but Wellverse IPO execution depends on standalone margin stabilization and equity-market conditions.